Navigation Links
Vaccine hope for skin cancer sufferers
Date:5/26/2010

Nottingham scientists have been given the green light to test a vaccine which they hope could reverse, and even cure malignant melanoma, the most deadly type of skin cancer.

Scancell Holdings plc, led by Professor Lindy Durrant of the University's Division of Clinical Oncology within the School of Molecular Medical Sciences, believes the new vaccine, which targets tumour cells without damaging healthy tissue, could be successful in treating patients with malignant melanoma.

Incidences of malignant melanoma have more than quadrupled over the past 30 years and in the last 25 years rates of malignant melanoma have risen faster than for any other cancer. It is now the most common cancer in younger adults aged 15 to 34, which may be linked to risky associated behaviour such as exposure to the sun on foreign beach holidays and the use of tanning booths. Every year, most of the 2,000 skin cancer deaths result from malignant melanoma.

Professor Durrant said: "Up until now, early diagnosis has been a crucial factor in the successful treatment of this disease. In the early stages it can be cured by completely removing the skin melanoma by surgery. However, in cases where it has not been picked up until further down the line, we have found that chemotherapy and radiotherapy simply do not work, although new compounds are being tested.

"It is still at a very early stage and impossible to predict the outcome of the clinical trial but if our results from the lab are replicated in patients I think we have a good chance of dramatically improving the chances of successful treatment we are hoping that the vaccine will cure between 10 and 20 per cent of patients with malignant melanoma."

Testing for the new SCIB1 vaccine has been given approval by the Gene Therapy Advisory Committee and the Medicines and Healthcare products Regulatory Agency and clinical trials are due to start shortly at Nottingham City Hospital and centres in Manchester and Newcastle.

It will initially be given to patients who are suffering from advanced malignant melanoma which has spread to other parts of the body.

The new vaccine works by activating the body's own natural defence systems it contains DNA and genetic material from tumours meaning it 'switches' on the specific immune cells that target melanoma. This means that it targets only the cancer and not the surrounding healthy tissue.

The team of scientists believe that, in principle, new vaccines based upon the same principle could also be used to target other types of cancer tumours, such as breast and prostate.


'/>"/>
Contact: Lindy Durrant
lindy.durrant@nottingham.ac.uk
44-011-582-31863
University of Nottingham
Source:Eurekalert

Related medicine news :

1. Mount Sinai researchers move closer to a universal influenza vaccine
2. A new cancer vaccine starves tumors of blood
3. Experimental Vaccine Shields Monkeys Against Ebola
4. Smallpox Vaccine May Protect Against HIV
5. Doctors Can Use Rotavirus Vaccine Again: FDA
6. Rotavirus Vaccine Helps Kids Avoid Severe Gastro Illness
7. Study finds rotavirus vaccine greatly reduces hospitalizations for acute gastroenteritis in children
8. Response to vaccines could depend on your sex
9. Misinformation About Vaccine Safety Puts Kids at Risk of Illness
10. New vaccines may come from forcing giardia parasite to display its many disguises
11. Prostate Cancer Vaccine Gains FDA Approval
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2017)... ... April 23, 2017 , ... Altura Communication Solutions, ... of Cisco Select certification and SMB specialization. Altura is now qualified to ... In earning the Select Certification, Altura fulfilled the training and exam requirements for ...
(Date:4/22/2017)... White Plains, NY (PRWEB) , ... April 22, ... ... Quarterly Report, which shows that U.S. consumers can save an average of 70% ... Even greater savings (up to 97%) are available when purchasing from other countries. ...
(Date:4/21/2017)... ... April 21, 2017 , ... An April 10 article ... ancient teeth, which reveal a great deal about prehistoric ice-age dental practitioners and their ... have been used to remove decayed dental matter, and that teeth were then filled ...
(Date:4/21/2017)... ... 21, 2017 , ... Contrary to popular perception, a new ... at noteworthy rates. Between 2002 and 2014, Salas-Wright and his colleagues found a ... the United States. The study, Trends in Fighting and Violence Among Adolescents ...
(Date:4/21/2017)... ... ... Brady (NYSE:BRC), a global leader in industrial and safety printing ... vinyl label materials received certification for the BS5609 British Marine Standard. This internationally recognized ... for use on chemical drums shipped by sea. , ÔÇťAchieving BS5609 certification ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production ... report to their offering. ... "Global Biosimilar Pipeline and Market Prospects: ... Design" provides an in-depth assessment of the current trends ...
(Date:4/20/2017)...  AbbVie (NYSE: ABBV), a global biopharmaceutical company, ... hepatitis C virus (HCV) infected patients with genotype ... cirrhosis (Child-Pugh A) achieved sustained virologic response at ... investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high ... weeks of G/P treatment without ribavirin. Patients with ...
(Date:4/19/2017)... Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that it will ... at the Sheraton Hotel in Toronto, Ontario . ... Company is scheduled to present on Tuesday, May 2 at 10:00 ... of the Board, Tony Holler will also attend the ... For more details about ...
Breaking Medicine Technology: